PRODUCT PIPELINE

our focus

Problem & Opportunity

No FDA approved drugs

  • Proven animal models for rapid screening
  • Local delivery method improves outcomes with fewer off-target concerns
  • Federal funding for initial studies 
  • Team of recognized experts across range of auditory maladies 

three men carrying
Product Pipelines

Robust pipeline for science-based solutions to hearing disorders

We have developed animal model systems for pre-clinical trials of drug candidates and have advanced our leading drug candidate to a clinical Phase II trial with the US Army. NIH-supported research is now enabling us to move additional candidates through our discovery pipeline.

Three Indications

NIHL

Prevalence of hearing loss and tinnitus in military population are greater than in the general public

Tinnitus

Hearing loss is the most common work-related illness in the U.S.

Meniere’s disease

Characterized by fluctuating hearing loss, often debilitating vertigo and roaring tinnitus that occurs in an episodic fashion. It’s estimated that there are 600,000-750,000 cases of Ménière’s disease in the United States.

Products

2
Patents Filed
5
Papers Published
7
SBIR/STTR Grants Received

Our Strategy

New Drug Development

Discovering new product formulations that fine-tune drug delivery to the ear.

New Drug Development

Discovering new product formulations that fine-tune drug delivery to the ear.

Targeted Delivery

Researching new Adeno-Associated Virus (AAV)-based tools to target cells in the auditory pathway (or auditory system) to fight against hearing loss.

Targeted Delivery

Researching new Adeno-Associated Virus (AAV)-based tools to target cells of the inner ear to fight against hearing loss.

Telehealth

Developing an online therapy for tinnitus management

Drug Repurposing

Based on clinically-validated tinnitus activities treatment therapy